Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
Munoz
M A
MA
Nephrology Department, Hospital 12 de Octubre, Madrid, Spain.
Andrés
A
A
Gallego
R
R
Morales
E
E
Morales
J M
JM
Aguado
J M
JM
Lumbreras
C
C
Torres
A
A
Rodicio
J L
JL
Praga
M
M
D000328:Adult; D000367:Age Factors; D000956:Antigens, Viral / Q000097:blood; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology / Q000821:virology; D012189:Retrospective Studies; D014019:Tissue Donors / Q000706:statistics & numerical data
D000956:Antigens, Viral; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D009173:Mycophenolic Acid